Which of these updates will have the biggest long-term impact on your area of practice
Adults With Obesity or Overweight in Clinical Trials A phase 2 obesity trial evaluated once-weekly subcutaneous retatrutide in adults with obesity or overweight without type 2 diabetes and reported substantial dose-dependent reductions in body weight at 24 and 48 weeks [4]
Proteomic analysis of differentially expressed proteins in the heart suggested activation of coagulation factor FXII, negative regulation of proteolysis, and, collectively, downregulation of kininogen
The ultimate result is more than merely an altered chest
Fatigue, insulin resistance, postpartum shifts, stress, and sleep deprivation all play a role
Best practices and progress in precision-cut liver slice cultures